BioCentury | Mar 21, 2016
Product Development

Korea rising

...gained rights to Nant-paclitaxel ( Cynviloq ), an injectable nanoparticle formulation of paclitaxel from Samyang Corp. Samyang...
...South Korea Qurient Co. Ltd. (KOSDAQ:115180), Seongnam, South Korea RegeneRx Biopharmaceuticals Inc. (OTCBB:RGRX), Rockville, Md. Samyang Corp....
BioCentury | Jun 22, 2015
Company News

Sorrento, NantWorks deal

...cancer. Sorrento has exclusive rights to Cynviloq in North America, the EU and Australia from Samyang Corp....
BioCentury | May 25, 2015
Company News

Samyang, Sorrento deal

...rights to the injectable nanoparticle formulation of paclitaxel in Australia, North America and the EU. Samyang...
...provide specific financial details, and Samyang could not be reached (see BioCentury, Feb. 17, 2014). Samyang Corp....
BioCentury | Feb 5, 2015
Product R&D

Addex's allosterics

...Inc. (OTCBB:CORX) CX1739 AMPA glutamate receptor (GRIA; GLUR) PAM Phase II Respiratory distress syndrome (RDA) Samyang Corp....
BioCentury | May 16, 2014
Financial News

Sorrento raises $25 million in follow-on

...Australia through its September acquisition of Igdrasol Inc. , which has rights from Samyang Corp. (KSE:000070). Samyang...
BioCentury | Apr 7, 2014
Clinical News

Cynviloq: Pivotal trial started

...Cynviloq in the U.S., EU, Mexico, Canada and Australia from Samyang (see BioCentury, Feb. 17). Samyang...
...Genexol-PM. Celgene Corp. (NASDAQ:CELG, Summit, N.J.) markets Abraxane. Sorrento Therapeutics Inc. (NASDAQ:SRNE), San Diego, Calif. Samyang Corp....
BioCentury | Feb 17, 2014
Company News

Sorrento, Samyang deal

...rights to the injectable nanoparticle formulation of paclitaxel in the U.S. and EU. Last May, Samyang...
...to Sorrento and Igdrasol Inc. and U.S. rights to Igdrasol. Sorrento acquired Igdrasol in September. Samyang...
...breast cancer and non-small cell lung cancer (NSCLC). Sorrento Therapeutics Inc. (NASDAQ:SRNE), San Diego, Calif. Samyang Corp....
BioCentury | Nov 18, 2013
Company News

Sorrento cancer news

...September acquisition of Igdrasol Inc. , which has rights from Samyang Corp. (KSE:00070, Seoul, South Korea). Samyang...
BioCentury | Oct 26, 2013
Financial News

Sorrento raises $30 million, moves to NASDAQ

...Cynviloq through its September acquisition of Igdrasol Inc. , which has rights from Samyang Corp. (KSE:00070). Samyang...
BioCentury | Oct 21, 2013
Company News

Sherrington Pharmaceuticals, Sorrento deal

...acquired exclusive, U.S. rights through the acquisition of Igdrasol Inc. , which received rights from Samyang Corp....
Items per page:
1 - 10 of 25
BioCentury | Mar 21, 2016
Product Development

Korea rising

...gained rights to Nant-paclitaxel ( Cynviloq ), an injectable nanoparticle formulation of paclitaxel from Samyang Corp. Samyang...
...South Korea Qurient Co. Ltd. (KOSDAQ:115180), Seongnam, South Korea RegeneRx Biopharmaceuticals Inc. (OTCBB:RGRX), Rockville, Md. Samyang Corp....
BioCentury | Jun 22, 2015
Company News

Sorrento, NantWorks deal

...cancer. Sorrento has exclusive rights to Cynviloq in North America, the EU and Australia from Samyang Corp....
BioCentury | May 25, 2015
Company News

Samyang, Sorrento deal

...rights to the injectable nanoparticle formulation of paclitaxel in Australia, North America and the EU. Samyang...
...provide specific financial details, and Samyang could not be reached (see BioCentury, Feb. 17, 2014). Samyang Corp....
BioCentury | Feb 5, 2015
Product R&D

Addex's allosterics

...Inc. (OTCBB:CORX) CX1739 AMPA glutamate receptor (GRIA; GLUR) PAM Phase II Respiratory distress syndrome (RDA) Samyang Corp....
BioCentury | May 16, 2014
Financial News

Sorrento raises $25 million in follow-on

...Australia through its September acquisition of Igdrasol Inc. , which has rights from Samyang Corp. (KSE:000070). Samyang...
BioCentury | Apr 7, 2014
Clinical News

Cynviloq: Pivotal trial started

...Cynviloq in the U.S., EU, Mexico, Canada and Australia from Samyang (see BioCentury, Feb. 17). Samyang...
...Genexol-PM. Celgene Corp. (NASDAQ:CELG, Summit, N.J.) markets Abraxane. Sorrento Therapeutics Inc. (NASDAQ:SRNE), San Diego, Calif. Samyang Corp....
BioCentury | Feb 17, 2014
Company News

Sorrento, Samyang deal

...rights to the injectable nanoparticle formulation of paclitaxel in the U.S. and EU. Last May, Samyang...
...to Sorrento and Igdrasol Inc. and U.S. rights to Igdrasol. Sorrento acquired Igdrasol in September. Samyang...
...breast cancer and non-small cell lung cancer (NSCLC). Sorrento Therapeutics Inc. (NASDAQ:SRNE), San Diego, Calif. Samyang Corp....
BioCentury | Nov 18, 2013
Company News

Sorrento cancer news

...September acquisition of Igdrasol Inc. , which has rights from Samyang Corp. (KSE:00070, Seoul, South Korea). Samyang...
BioCentury | Oct 26, 2013
Financial News

Sorrento raises $30 million, moves to NASDAQ

...Cynviloq through its September acquisition of Igdrasol Inc. , which has rights from Samyang Corp. (KSE:00070). Samyang...
BioCentury | Oct 21, 2013
Company News

Sherrington Pharmaceuticals, Sorrento deal

...acquired exclusive, U.S. rights through the acquisition of Igdrasol Inc. , which received rights from Samyang Corp....
Items per page:
1 - 10 of 25